For research use only. Not for therapeutic Use.
MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.
| Catalog Number | I013741 |
| CAS Number | 1857417-13-0 |
| Molecular Formula | C₂₈H₂₇F₃N₈S |
| Purity | ≥95% |
| Target | Epigenetic Reader Domain |
| Solubility | 10 mM in DMSO |
| IUPAC Name | 4-methyl-1-(1H-pyrazol-4-ylmethyl)-5-[[4-[[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]indole-2-carbonitrile |
| InChI | InChI=1S/C28H27F3N8S/c1-17-19(2-3-25-23(17)8-21(11-32)39(25)14-18-12-35-36-13-18)15-38-6-4-20(5-7-38)37-26-24-9-22(10-28(29,30)31)40-27(24)34-16-33-26/h2-3,8-9,12-13,16,20H,4-7,10,14-15H2,1H3,(H,35,36)(H,33,34,37) |
| InChIKey | DETOMBLLEOZTMZ-UHFFFAOYSA-N |
| SMILES | CC1=C(C=CC2=C1C=C(N2CC3=CNN=C3)C#N)CN4CCC(CC4)NC5=C6C=C(SC6=NC=N5)CC(F)(F)F |
| Reference | [1]. Borkin D, et al. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 2015 Apr 13;27(4):589-602. |
